Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГНЦ социальной и судебной психиатрии им. В.П.Сербского, Москва
Список исп. литературыСкрыть список 1. Ястребов Д.В., Аведисова А.С. Некоторые аспекты терапии атипичными антипсихотическими препаратами. Соврем. терапия в психиатрии и неврологии. 2012; 2: 10–4. 2. Allison D, Mentore J, Heo M et al. Antipsychotic induces weight gain: a comprehensive research synthesis. Am J Psychiat 1999; 156: 1686–96. 3. Arana G, Rosenbaum J. Handbook of psychiatric drug therapy, 4th ed. 2001. 4. Baghdady NT, Banik S, Swartz SA et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009; 26: 404–24. 5. Beasley CM, Sanger T, Satterlee W et al. Olanzapine vs placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol 1996; 124: 159–67. 6. Bergemann N, Frick A, Parzer P et al. Olanzapine plasma concentration, average daily dose, and interaction with comedication in schizophrenic patients. Pharmacopsyсhiatry 2004; 37: 63–8. 7. Brown S, Birtwisle J, Roe L et al. The unhealthy lifestyle of people with schizophrenia. Psychological Med 1999; 29: 697–701. 8. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177–93. 9. Campbell M, Young PI, Bateman DN et al. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol 1999; 47 (1): 13–22. 10. Cohen LG, Fatalo A, Thompson BT et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34: 275–8. 11. Cooperberg AA, Edlow S. Haemolytic anemia, jaundice and diabetes mellitus folowing chlorpromazine therapy. J Can Med Associat 1956; 75: 746–9. 12. Farde L, Nordstrom AL, Wiesel FA et al. Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extra pyramidal side effects. Arch Gen Psychiat 1992; 49: 538–44. 13. Freeman H. Resistance to insulin in mentally disturbed soldiers. Archives of Neurology and Psychiat 1946; 56: 74–7. 14. Gaebel W, Riesbeck M, Wölwer W et al. Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiat 2011; 72 (2): 205–18. 15. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002; 59: s22–6. 16. Gautam D, Han SJ, Hamdan FF et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006; 3 (6): 449–61. 17. Gossen D, de Suray JM, Vandenhende F et al. Influence of fluoxetine on olanzapine pharmacokineties. AAPS Pharm Sci 2002; 4: 1. 18. Haase HJ, Janssen PA. The action of neuroleptic drugs. Chicago, IL. Year Book Medical, 1965. 19. Haddad PM. Antipsychotics and diabetes: review of non-prospective data. British J Psychiat 2004; 184 (Suppl. 47): s80–6. 20. Harvey EJ, Taylor DM, Flanagan RJ. D2-receptor occupancy under recommended and high doses of olanzapine. J Psychopharmacol 2001; 15: 213–4. 21. Haslemo T, Eikeseth PH, Tanum L et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049–53. 22. Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011; 71 (4): 611–5. 23. Hiemke C, Peled A, Jabarin M et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002; 22: 502–6. 24. Hiles BW. Hyperglycemia and glucosuria following chlorpromazine therapy (letter). JAMA 162; 1651. 25. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of Gen Psychiat 1988; 45: 789–96. 26. Kapur S, Zipursky RB, Remington G et al. 5HT2- and D2-receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiat 1998; 155: 921–8. 27. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999; 40: 101–4. 28. Kelly DL, Richardson CM, Yu Y et al. Plasma concentrations of high-dose olanzapine in a double-blind erossover study. Hum Psychopharmacol 2006; 21: 393–8. 29. Kinon BJ, Basson BR, Gilmore JA et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiat 2000; 61: 833–40. 30. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28 (4): 392–400. 31. Lambert T. Hares and tortoises: long-term antipsychotic weight gain. 7th Biennal Australian Schizophrenia Conference. 24–26 Oct 2002; Sydney, NSW. 32. Lorenz W. Sugar tolerance in dementia praecox and other mental disorders. Archives of Neurology and Psychiat 1922; 8; 184–96. 33. Markowitz JS, De Vane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. J Clin Psychopharmacol 1999; 19: 289–91. 34. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion. J Clin Psychiat 2005; 7: 121–9. 35. Mauri MC, Volonteri LS, Colasanti A et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359–88. 36. McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiat 2007; 164 (7): 1050–60. 37. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacol (Berl) 2003; 170: 157–66. 38. Silverman RB. The organic chemistry of drug design and drug action. Academic press, San Diego 1992. 39. Thakore JH. Metabolic syndrome and schizophrenia. Brit J Psychiat 2005; 186: 455–6. 40. Theisen FM, Haberhausen M, Schulz E et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006; 28: 750–9. 41. Thornnard-Neumann E. Phenotiazine and diabetes in hospitalized women. Am J Psychiat 1986; 124: 978–82. 42. Wu TH, Chiu CC, Shen WW et al. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiat 2008; 32: 1889–93.